Comparison between Pradaxa vs Eliquis
| Parameter | Pradaxa | Eliquis |
|---|---|---|
| Class | DOAC thrombin inhibitor | DOAC Xa inhibitor |
| Mechanism | Direct thrombin inhibition | Factor Xa inhibition |
| Onset | Rapid | Rapid |
| Monitoring | None | None |
| Dosing | BD | BD |
| Half-life | ~12-17h | ~12h |
| Reversal Agent | Idarucizumab | Andexanet |
| Bleeding Risk | Moderate | Lower |
| Indications | AF/VTE | AF/VTE |
| Renal Use | Caution | Caution |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Moderate | Moderate |
| Adherence Sensitivity | High | High |
| Best Use Case | Specific reversal | Better bleed profile |
| Cost | High | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | Moderate | High |
| Overall Verdict | Reversible | Safer |
| Food Interactions | None | None |